The finished-drug facility targets what he sees as an underserved need for sterile drug production in high-tech areas such as oncology and antibody-drug conjugates at late-stage clinical and early-commercial scale. “We see a big appetite for customers that want small commercial batches, not 50 million vials a month,” he says.
by Rick Mullin | August 27, 2020
/pharmaceuticals/oncology/BMS-pay-475-million-Dragonflys/98/i32 20200821 Concentrates 98 32 /magazine/98/09832.html BMS to pay $475 million for Dragonfly’s IL-12 program oncology, pharmaceuticals, il-12, bms, dragonfly con bus Ryan Cross pharmaceuticals oncology business BMS will license Dragonfly’s IL-12 drug Chemical & Engineering News BMS to pay $475 million for Dragonfly’s IL-12 program BMS to pay $475 million for Dragonfly’s IL-12 program
by Ryan Cross | August 21, 2020
Eli Lilly and Company’s $8 billion acquisition of Loxo Oncology in 2019 also included a noncovalent BTK inhibitor. BTK is linked to inflammation as well, and Principia focuses on developing BTK inhibitors for immune system diseases and multiple sclerosis. Its compound rilzabrutinib is in clinical trials for pemphigus and immune thrombocytopenia.
by Ryan Cross | August 21, 2020
/pharmaceuticals/oncology/Lingyin-Li/98/i31 20200814 Multidisciplinary maven is harnessing the immune system to fight cancer 98 31 /magazine/98/09831.html Lingyin Li Cancer, talented 12, Lingyin Li scitech Laura Howes pharmaceuticals oncology people profiles biological-chemistry biochemistry Li discovered that an enzyme called ENPP1 clears the signaling molecule cGAMP when it has moved outside of cells.
by Laura Howes | August 14, 2020
/pharmaceuticals/oncology/AstraZeneca-licenses-another-Daiichi-cancer/98/i30 20200802 Concentrates 98 30 /magazine/98/09830.html AstraZeneca licenses another Daiichi cancer drug Antibody-drug conjugate, oncology, linker con bus Michael McCoy pharmaceuticals oncology business AstraZeneca licenses another Daiichi drug Chemical & Engineering News AstraZeneca licenses another Daiichi cancer drug AstraZeneca licenses another Daiichi cancer drug
by Michael McCoy | August 02, 2020
/biological-chemistry/synthetic-biology/Bright-Peak-launches-synthetic-proteins/98/i30 20200731 Concentrates 98 30 /magazine/98/09830.html Bright Peak launches for synthetic proteins Synthetic proteins, oncology, amino acids con bus Lisa M. Jarvis biological-chemistry synthetic-biology pharmaceuticals drug-development business Bright Peak launches for synthetic proteins Chemical & Engineering News Bright Peak launches for synthetic proteins Bright Peak launches for synthetic proteins
by Lisa M. Jarvis | July 31, 2020
The American Society of Clinical Oncology (ASCO) annual meeting, held in May, and the Green Chemistry & Engineering Conference (GC&E), held in June, offered entirely virtual content in place of their in-person meetings. Many of us have also enjoyed the virtual seminars being offered by ACS divisions.
by Rick Ewing | July 31, 2020
Nuclear innovation company TerraPower hopes nuclear waste can supply it 98 29 /magazine/98/09829.html Mining medical isotopes from nuclear waste Actinium, Thorium, Nuclear waste, alpha particle, chemotherapy, uranium scitech Wudan Yan, special to C&EN physical-chemistry nuclear-chemistry biological-chemistry cancer pharmaceuticals oncology A column at Oak Ridge National Laboratory binds thorium-229 while actinium-225 and other elements pass through, a process called “milking the thorium cow.”
by Wudan Yan, special to C&EN | July 27, 2020
—Kronos buys Gilead’s SYK inhibitors “” Gilead Sciences has licensed its spleen tyrosine kinase (SYK) inhibitors to the oncology-focused biotech firm Kronos Bio. The collection of small molecules includes entospletinib, which has already gone through multiple Phase II studies in blood cancers, and lanraplenib, which has completed Phase II trials in lupus and other autoimmune diseases.
by Lisa M. Jarvis | July 25, 2020